These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent. Van der Plas SE; Kelgtermans H; De Munck T; Martina SLX; Dropsit S; Quinton E; De Blieck A; Joannesse C; Tomaskovic L; Jans M; Christophe T; van der Aar E; Borgonovi M; Nelles L; Gees M; Stouten P; Van Der Schueren J; Mammoliti O; Conrath K; Andrews M J Med Chem; 2018 Feb; 61(4):1425-1435. PubMed ID: 29148763 [TBL] [Abstract][Full Text] [Related]
6. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772 [TBL] [Abstract][Full Text] [Related]
7. A common mechanism for CFTR potentiators. Yeh HI; Sohma Y; Conrath K; Hwang TC J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713 [TBL] [Abstract][Full Text] [Related]
8. Corrector combination therapies for F508del-CFTR. Hanrahan JW; Matthes E; Carlile G; Thomas DY Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476 [TBL] [Abstract][Full Text] [Related]
9. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1). Davies JC; Van de Steen O; van Koningsbruggen-Rietschel S; Drevinek P; Derichs N; McKone EF; Kanters D; Allamassey L; Namour F; de Kock H; Conrath K J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302 [TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
11. Entering the era of highly effective modulator therapies. Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412 [TBL] [Abstract][Full Text] [Related]
12. Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Hoy SM Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874 [TBL] [Abstract][Full Text] [Related]
13. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related]
14. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
15. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
16. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Shaughnessy CA; Zeitlin PL; Bratcher PE Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919 [TBL] [Abstract][Full Text] [Related]
17. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy. Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004 [TBL] [Abstract][Full Text] [Related]
18. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR. Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810 [TBL] [Abstract][Full Text] [Related]
19. Sites associated with Kalydeco binding on human Cystic Fibrosis Transmembrane Conductance Regulator revealed by Hydrogen/Deuterium Exchange. Byrnes LJ; Xu Y; Qiu X; Hall JD; West GM Sci Rep; 2018 Mar; 8(1):4664. PubMed ID: 29549268 [TBL] [Abstract][Full Text] [Related]
20. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]